Skip to content

Investors Overview

Esperion is a pharmaceutical company passionately committed to developing and commercializing non-statin, once-daily, oral therapies to lower elevated low-density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid is being developed as a once-daily, oral inhibitor of ATP Citrate Lyase (ACL), and is designed to bring a targeted mechanism of action to address patients’ unmet medical needs.

Esperion has been a publicly traded company since 2013 and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics () on
Last Price Change open Day High 52-Week High
Volume Previous Close Day Low 52-Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Date Title and Summary
Toggle Summary ESPERION Reports Preliminary Fourth Quarter 2020 Financial Results and Further Commits to Unmet Patient Needs with Oral PCSK9 Inhibitor Program
– Fourth-quarter 2020 U.S. net product revenue estimated between $8.0 and $8.5 million – – Range represents over 140 percent sequential growth for NEXLETOL ® (bempedoic acid) tablets and NEXLIZET ® (bempedoic acid and ezetimibe) tablets – – Company provides full-year 2021 operating expense guidance
Toggle Summary Esperion to Present at the 39th Annual J.P. Morgan Healthcare Conference
ANN ARBOR, Mich., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Tim M. Mayleben, will present at the virtual 39 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 7:30 a.m.
Toggle Summary First-in-class cholesterol-lowering treatment NILEMDO® * (bempedoic acid) tablet and its combination with ezetimibe NUSTENDI® * (bempedoic acid and ezetimibe) tablet approved in Switzerland
- NILEMDO ® (bempedoic acid) is the first oral, once-daily treatment approved in almost two decades to lower low-density lipoprotein cholesterol (LDL-C) for indicated patients - - Bempedoic acid and its fixed combination drug product with ezetimibe both deliver significant reductions in LDL-C when
Toggle Summary ESPERION Appoints Sheldon Koenig as Chief Operating Officer
ANN ARBOR, Mich., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Sheldon Koenig, a proven leader in the cardiovascular market, as chief operating officer, effective today. Koenig will report directly to Tim M.
Toggle Summary NEXLETOL® (bempedoic acid) Tablets Highlighted at AHA 2020 with Presentations of Analyses Demonstrating Significant Low-Density Lipoprotein Cholesterol (LDL-C) Lowering vs. Placebo in Phase 3 Study Subgroups
- Significant mean reduction of 26.5% in LDL-C with bempedoic acid vs. placebo in pooled analysis of people who cannot tolerate statins 1 - - Analysis by sex showed bempedoic acid significantly lowered LDL-C at week 12 in males and females * vs. placebo 2 - ANN ARBOR, Mich., Nov.
Load More